Trump Proposes 100% Tariff on Imported Generic Drugs Starting in 2028

U.S. President Donald Trump announced a plan on Tuesday evening to impose a 100% tariff on all imported generic drugs, with the new trade barrier scheduled to take effect in 2028. The policy is intended to compel pharmaceutical companies to move their manufacturing operations back to the United States.

Details of the Tariff Proposal

In a post on his Truth.Social platform, the President outlined a phased approach to the new import duties. According to the announcement, the policy includes:

• A two-year exemption period where generic drugs will continue to be imported without tariffs.
• A 100% duty applied to all generic drug imports starting in 2028.
• A subsequent increase of the tariff to 200% at an unspecified later date.

Trump stated the policy is designed to “RESHORE Generic Pharmaceutical Production into America, with a penalty to those Companies that decide not to build Plant and Equipment within the stated period of time given to them.”

Policy Goals and Exemptions

Ad

The administration's stated goal is to bolster the domestic pharmaceutical industry and reduce reliance on foreign supply chains. This measure follows a previous proclamation that imposed 100% tariffs on imported patented pharmaceuticals.

President Trump indicated that companies could receive exemptions from the tariffs. One path to exemption is by constructing drug production facilities within the United States. Another potential exemption involves adopting a “most favored nation” pricing model, where companies would agree to charge U.S. buyers the same price paid by other countries.

Market Implications

This proposed tariff structure represents a significant potential shift for the U.S. pharmaceutical market, which relies heavily on imported generic drugs to control healthcare costs. If implemented, the policy could create substantial inflationary pressure on drug prices for consumers and healthcare providers.

For investors, the announcement creates a clear distinction between potential winners and losers. Domestic pharmaceutical manufacturers could benefit from reduced foreign competition, while generic drug importers and companies with globalized supply chains would face significant cost increases and operational challenges. The two-year grace period is designed to give companies time to adjust their manufacturing and sourcing strategies ahead of the 2028 implementation date.